Article Text

Download PDFPDF
JUPITER randomised controlled trial
Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men
  1. Andrew Leventhal1,2,
  2. Erin D Michos1
  1. 1Johns Hopkins University School of Medicine, Bethesda, Maryland, USA
  2. 2The National Institutes of Health, Bethesda, Maryland, USA
  1. Correspondence to Erin D Michos
    Division of Cardiology, Johns Hopkins University School of Medicine, Carnegie 568, 600 N. Wolfe Street, Baltimore, MD 21287, USA; edonnell{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:

Although the efficacy of statins in women with coronary artery disease (CAD) is established and similar to that noted in men, their benefit in preventing events in asymptomatic women is controversial. A meta-analysis concluded that statins reduce CAD in men without prior disease but that in women the reduction was not statistically significant.1 However, this analysis did not include the largest primary prevention trial, the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).2 After analysing sex-specific outcomes from JUPITER and including them in an updated meta-analysis, Mora and colleagues conclude that statins are effective for primary prevention in selected women.

Sex-specific analysis of JUPITER

JUPITER enrolled 6801 women aged ≥60 years without prior CAD, stroke or diabetes who had LDL-cholesterol (LDL-C) <130 mg/dl and high-sensitivity C-reactive protein (hsCRP) ≥2.0 mg/l. Patients were …

View Full Text


  • Competing interests None.